Statics from the National Cancer Institute indicate that 14.5 million U.S. citizens were living with cancer in 2014.If proper measures are not taken, the figures might rise by over four million, hitting about 19 million by 2024 and more information click here.
However, things might just change for the better, with advances in technologies fronted by companies such as Tempus. The company comes into the picture at a time when Electronic Health Records (EHR) is gaining popularity, though gradually.
With Tempus, clinical information regarding the patient is combined and analyzed with molecular information collected through genome sequencing, to give more accurate and reliable outcome.This detailed interrogation is highly useful as researchers try to make in-depth analysis of cancer at larger.
Eric Lefkofsky, co-founder, and CEO of Tempus, first got an up and close experience with cancer patients when his wife was diagnosed with the disease. The tech-savvy co-founder of another startup, Groupon, was utterly amazed by the gaping holes in the technology used for cancer treatment.An influential figure in tech-matters, Lefkofsky set to build Tempus, which aims at making comprehensive genomic analysis using individual patient’s DNA.Tempus is a foresighted undertaking that will contribute significantly to the treatment of cancer and what Eric knows.
Eric Lefkofsky was born in Southfield, Michigan.The forty-eight-year-old graduated from the University of Michigan in 1991 and earned his Juris Doctor degree the same university two years later.A top academic achiever graduating with honors, Lefkofsky has taught at DePaul University’s Kellstadt Graduate School of Business as well as Northwestern University’s Kellogg School of Management and is presently a professor at the University of Chicago and Eric’s lacrosse camp.
Headquartered in Chicago where Eric Lefkofsky has spent most of his adult life, Tempus is seen as greatly revolutionary, especially at a time when the world stares confusedly at the challenges posed by cancer.
The success of Tempus might add a much-needed relief to the focus that has been given to human molecular and cellular levels as well as genetic composition in the treatment of cancer.Eric Lefkofsky hopes to draw from his previous successes with startups and business in general, to drive Tempus to the next level.